Core Insights - OPKO Health, Inc. will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, in San Francisco [1] - Management will host one-on-one meetings with investors and present on January 15 at 3:00 p.m. Pacific time, with the presentation available for live webcast and replay [1] Company Overview - OPKO Health is a multinational biopharmaceutical and diagnostics company focused on establishing industry-leading positions in large, rapidly growing markets through its discovery, development, and commercialization expertise [2]

OPKO Health, Inc.’s (OPK) company, ModeX Therapeutics Inc., announced the dosing of the first participant in the Phase I study (NCT06655324) of an Epstein-Barr virus (EBV) vaccine candidate yesterday. The EBV vaccine is being developed in collaboration with Merck, which is known as MSD outside the United States and Canada.Per management, the first participant has been dosed with novel investigational EBV vaccine targeting multiple viral proteins in the Phase I study.It is worth mentioning that this developm ...

Core Insights - ModeX Therapeutics Inc., a subsidiary of OPKO Health, has initiated a Phase I clinical trial for an Epstein-Barr Virus (EBV) vaccine candidate, MDX2201, in collaboration with Merck, which has triggered a cash milestone payment from Merck to ModeX [1][2][4]. Company Overview - ModeX Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative multispecific biologics for cancer and infectious diseases, utilizing a unique technology platform [7]. - OPKO Health is a multinational biopharmaceutical and diagnostics company aiming to establish leading positions in rapidly growing markets through its discovery and development capabilities [8][9]. Vaccine Development - The investigational vaccine, MDX2201, is based on a ferritin nanoparticle platform that can express multiple copies of recombinant antigens to enhance immune response against EBV [5]. - The vaccine targets four viral proteins involved in EBV entry into host cells, aiming to stimulate protective immunity and prevent diseases associated with EBV [5][6]. Clinical Trial Details - The Phase I study will evaluate the safety and tolerability of MDX2201 in up to 200 healthy adults [3]. - The vaccine aims to address the lack of FDA-approved vaccines or treatments for EBV, which is linked to infectious mononucleosis and various cancers [6][8].

Epstein-Barr virus (EBV) causes infectious mononucleosis and is associated with several types of cancer and multiple sclerosisThere are no current treatments or vaccines for EBVFirst participant dosed with novel investigational EBV vaccine targeting multiple viral proteins in Phase I study WESTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ:OPK), announces dosing of the first participant in the Phase I study (NCT06655324) of an EBV vaccine candidate being ...

OPKO Health, Inc. (OPK) delivered an earnings per share (EPS) of 3 cents in the third quarter of 2024 against the year-ago period’s loss of 11 cents per share and the Zacks Consensus Estimate of a loss of 10 cents per share.OPK’s Revenues in DetailOPKO Health registered revenues of $173.6 million in the third quarter, down 2.8% year over year. The figure missed the Zacks Consensus Estimate by 4.3%.Lower revenues from products and services dragged the overall top line.Shares of this company gained nearly 4.1 ...

For the quarter ended September 2024, OPKO Health (OPK) reported revenue of $173.6 million, down 2.8% over the same period last year. EPS came in at $0.03, compared to -$0.11 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $181.32 million, representing a surprise of -4.26%. The company delivered an EPS surprise of +130.00%, with the consensus EPS estimate being -$0.10.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wal ...

OPKO Health, Inc. (NASDAQ:OPK) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisor, IR Phillip Frost - Chairman and CEO Elias Zerhouni - Vice Chairman, President Adam Logal - CFO Conference Call Participants Maury Raycroft - Jefferies Yi Chen - H.C. Wainwright Edward Tenthoff - Piper Sandler Michael Petusky - Barrington Research Operator Good day, and welcome to the OPKO Health Third Quarter of 2024 Financial Results Conference Call. All partici ...

OPKO Health (OPK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.10 per share. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 130%. A quarter ago, it was expected that this holding company with investments in pharmaceutical and diagnostics companies would post a loss of $0.09 per share when it actually produced a loss of $0.01, deliverin ...

OPKO Health, Inc.'s (OPK) company, ModeX Therapeutics Inc., was awarded $35 million of additional funding under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services on Monday. The funding brings the total support awarded to ModeX to $110 million out of $205 million if all options are executed. The funding is expected to support the development of a s ...

Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executed Development work is based on ModeX proprietary MSTAR technology that incorporates multiple antibody binding sites into a single molecule WESTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, announces it has been awarded $35 million of additional funding under a ...